Is Adjuvant Immunotherapy Worth for All Patients with Clear-cell Renal Cell Carcinoma at High Risk of Recurrence?
-
Marchioni, Michele (G. D'Annunzio University of Chieti)
;
Amparore, Daniele (University of Turin) ;
Marandino, Laura (IRCCS San Raffaele Scientific Institute (Milà, Itàlia)) ;
Bertolo, Riccardo (San Carlo Di Nancy Hospital) ;
Erdem, Selcuk (Istanbul University) ;
Ingels, Alexandre (University Hospital Henri Mondor) ;
Muselaers, Stijn (Radboud University Medical Center) ;
Kara, Onder (Kocaeli University School of Medicine) ;
Pavan, Nicola (University of Trieste) ;
Roussel, Eduard (University Hospitals Leuven (Bèlgica)) ;
Carbonara, Umberto (University of Bari) ;
Pecoraro, Angela (Pederzoli Hospital) ;
Diana, Pietro (Fundació Puigvert) ;
Pecoraro, Alessio (University of Florence) ;
Campi, Riccardo (University of Florence) ;
Universitat Autònoma de Barcelona
visitante ::
identificación
Subscribirse to this discussion. You will then receive all new comments by email.
